Fig.2
From: CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro
In vitro treatment response of HER2 + breast cancer to single agent trastuzumab. HER2 + breast cancer cells were treated with incremental doses of single agent trastuzumab therapy and longitudinal changes in cell confluence was observed over 7 days. In comparison to control groups, cancer cells treated with 25, 50 and 100 µg/mL were statistically similar (p = 0.38, 0.72 and 0.89 in BT474, SKBR3 and MDA-MB-453 cell lines, respectively) to one another and 25 µg/mL was used for subsequent experiments